Is your ankle cartilage damage suitable for ChondroFiller injection?

Focal ankle cartilage damage — particularly a contained lesion on the talar dome — is precisely the situation ChondroFiller injection is designed for. Whether the damage follows a sprain, an osteochondritis dissecans (OCD) lesion, or a fracture, the treatment may be appropriate if the defect is localised, has not resolved with conservative care, and the joint as a whole remains structurally sound.

The formal CE-mark threshold is Outerbridge grade III or IV cartilage damage — meaning partial- or full-thickness loss with fissuring, softening, or exposed subchondral bone. Early-stage or superficial change (grade I or II) does not meet this threshold. In clinical practice, the ideal ankle candidate presents with a focal, contained talar osteochondral lesion (OCL) that has already been through a course of conservative management: physiotherapy, anti-inflammatory medication, bracing, and, where indicated, corticosteroid injection. If those measures have not delivered meaningful improvement, ChondroFiller injection enters the conversation as a joint-preservation step — explicitly positioned before any discussion of joint replacement.

Post-traumatic presentations fit the indication particularly well. Chondral lesions, OCD, and damage arising after a ligament injury or ankle fracture all fall within scope, provided the surrounding joint structure is intact and the mechanics of the limb have been properly assessed. Diffuse or end-stage osteoarthritis sits outside this indication.

Defect size and location: the specific ankle criteria

The talar dome covers a relatively small articular surface and bears load-per-unit-area among the highest of any joint in the body. Those two factors explain why clinical guidance for the ankle applies a more conservative defect size window of approximately 1.0–1.2 cm², compared with the broader 6 cm² ceiling cited for the general ChondroFiller indication. A lesion that might be considered modest at the knee can represent a proportionally larger share of the talar surface.

Location matters as much as size. Around 83% of talar osteochondral lesions (OCLs) occur on the medial dome, which means most ankle candidates presenting for assessment are dealing with a medial lesion — often in the posteromedial zone, where OCD and post-traumatic damage most commonly arise. Lateral dome lesions are less frequent but remain within scope.

Containment is a further criterion: the defect should have a defined border rather than extending to the articular rim. Uncontained lesions — where the cartilage edge lacks a stable shoulder of surrounding tissue — are less suited to the injection pathway, since the scaffold requires a confined space in which to gel and consolidate.

MRI is the primary tool for confirming all three parameters before any injection decision is made. It characterises defect location, depth, and size, and — critically — establishes whether the lesion is contained and the subchondral bone beneath it is structurally sound.

Mechanical prerequisites: alignment and joint stability

Structural soundness matters as much as the cartilage defect itself. Before ChondroFiller injection is considered, the mechanical environment of the ankle must be assessed and — where problems are identified — corrected.

Untreated ligament laxity is a disqualifying condition in its current state. Chronic instability places the scaffold under shear forces it cannot withstand; without a stable joint, the collagen matrix cannot integrate properly and the biological repair process is compromised from the outset. Where laxity is present, it must be resolved first, through structured rehabilitation, bracing, or surgical stabilisation as appropriate.

Coronal malalignment — significant varus or valgus deformity — raises the same concern at the whole-limb level. Abnormal alignment concentrates load on one side of the talar surface, turning a focal lesion into a site of ongoing mechanical overload. Research published in 2025 draws a direct line between alignment and lesion location: varus lower-limb mechanics associate with medial-dome lesions, and valgus mechanics with lateral ones. Alignment assessment is therefore part of the candidacy workup itself, not a separate orthopaedic concern to be deferred.

The same principle governs the OA threshold. Kellgren-Lawrence grades I to III — mild to moderate disease with preserved joint space — represent the clinical sweet spot. Candidates at this stage retain sufficient joint architecture to benefit from a scaffold-based approach. Severe end-stage OA, with significant joint-space loss and diffuse articular destruction, is a clear disqualifying finding. At that point, the conversation appropriately shifts towards joint replacement rather than regenerative injection.

What the pre-injection assessment involves

Arriving at an assessment appointment, patients typically encounter three tools: an MRI scan review, a pain score, and a functional questionnaire. Together they build a clinical picture that determines whether the defect, the symptoms, and the joint as a whole meet the treatment threshold.

On MRI, the clinician is looking beyond size and containment — both of which will already have been considered — to confirm defect depth and the condition of the subchondral bone beneath the lesion. An intact or only modestly affected subchondral plate supports the scaffold's integration; significant bone oedema or cystic change at the base of the defect may alter the treatment plan.

Pain at baseline is recorded using the Visual Analogue Scale (VAS), a simple 0–10 measure that establishes a reference point for monitoring response over time. Functional limitation is captured with the WOMAC index, which covers pain with activity, joint stiffness, and day-to-day physical function across several questions.

The pattern that consistently associates with the strongest outcomes in available data is moderate pain combined with a clearly focal lesion on MRI and preserved joint space. The assessment is designed specifically to confirm whether a patient fits that profile. It takes place in an outpatient consultation — no theatre access, no anaesthesia, and no overnight admission is required at this stage.

How the ChondroFiller outpatient injection works

The injection itself takes only a few minutes, delivered under real-time ultrasound so the clinician can guide the needle precisely into the defect on the talar dome rather than relying on surface anatomy alone.

ChondroFiller arrives in a dual-component syringe. When the two chambers mix on delivery, the Type I collagen solution begins to polymerise inside the defect, forming a stable hydrogel scaffold that fills the contours of the lesion within approximately three to five minutes. No general anaesthetic is needed and no theatre slot is booked — this sits within a routine outpatient clinic appointment.

The mechanism is called acellular matrix-induced chondrogenesis. The scaffold contains no cells of its own; instead it creates a structured, three-dimensional environment that draws the patient's own progenitor cells — recruited from the surrounding synovium and from the subchondral bone beneath the defect — into the repair site. Those cells then begin to lay down new matrix within the scaffold. Put plainly, the injection supports the body's own repair processes; it does not independently regrow cartilage.

Published clinical evaluation data covering more than 19,000 units sold since 2013 reported no serious adverse incidents, a reassuring safety record for a relatively novel scaffold technology — though long-term randomised trial data remain limited.

After the procedure, a period of non-weight-bearing is required to allow the scaffold to stabilise, followed by a structured rehabilitation programme. Compliance with this protocol is a firm candidacy requirement, not an afterthought: the biological repair process cannot establish itself under uncontrolled mechanical load.

Contraindications, evidence gaps, and accessing treatment in London

The contraindications are straightforward. ChondroFiller injection is not suitable where there is an active joint infection, severe localised inflammation, or a confirmed allergy to murine-derived Type I collagen. Inability to observe the post-procedure non-weight-bearing period and follow a structured rehabilitation programme is equally disqualifying — the biological repair process the scaffold initiates requires controlled loading conditions to establish itself. It is also worth noting, in one honest sentence, that ankle-specific outcome data remain limited: published clinical evidence draws primarily from knee and other joint studies, and a dedicated ankle randomised controlled trial has not yet been completed.

In the UK, ChondroFiller injection is a self-funded private treatment, not currently available through the NHS or private medical insurance. Guide costs start from approximately £3,000.

Patients most likely to benefit are those with a confirmed focal talar lesion on MRI, a mechanically sound joint, and a realistic commitment to the recovery period — the profile this article has outlined throughout. For those who meet that description, Liquid Cartilage™ is delivered at the London Cartilage Clinic on Harley Street, where Professor Paul Y. F. Lee leads ChondroFiller injection treatment. Assessments can be booked via londoncartilage.com.